CN105998072A - 一种猪脑提取物、含有该猪脑提取物的组合物及其应用 - Google Patents
一种猪脑提取物、含有该猪脑提取物的组合物及其应用 Download PDFInfo
- Publication number
- CN105998072A CN105998072A CN201610547261.4A CN201610547261A CN105998072A CN 105998072 A CN105998072 A CN 105998072A CN 201610547261 A CN201610547261 A CN 201610547261A CN 105998072 A CN105998072 A CN 105998072A
- Authority
- CN
- China
- Prior art keywords
- sus domestica
- medulla sus
- extract
- compositions
- domestica extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 210000004556 brain Anatomy 0.000 title claims abstract description 17
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 31
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000843 powder Substances 0.000 claims abstract description 4
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 63
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000007710 freezing Methods 0.000 claims description 15
- 230000008014 freezing Effects 0.000 claims description 15
- 235000012054 meals Nutrition 0.000 claims description 14
- 238000000108 ultra-filtration Methods 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 12
- 102000057297 Pepsin A Human genes 0.000 claims description 9
- 108090000284 Pepsin A Proteins 0.000 claims description 9
- 102000004142 Trypsin Human genes 0.000 claims description 9
- 108090000631 Trypsin Proteins 0.000 claims description 9
- 229940111202 pepsin Drugs 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 7
- 238000001728 nano-filtration Methods 0.000 claims description 7
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims 1
- 239000010460 hemp oil Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 239000000787 lecithin Substances 0.000 abstract description 4
- 229940067606 lecithin Drugs 0.000 abstract description 4
- 235000010445 lecithin Nutrition 0.000 abstract description 4
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 abstract description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract 1
- 235000021388 linseed oil Nutrition 0.000 abstract 1
- 239000000944 linseed oil Substances 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 17
- 239000007788 liquid Substances 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229960004488 linolenic acid Drugs 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000009191 jumping Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 239000002893 slag Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000186685 Lactobacillus hilgardii Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000009189 diving Effects 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001312741 Gekko swinhonis Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N Xylose Natural products O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000017619 regulation of gastric acid secretion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
猪脑提取物 | γ-氨基丁酸 | 亚麻籽油粉 | |
实施例4 | 2g(实施例1) | 5g | 5g |
实施例5 | 5g(实施例2) | 10g | 10g |
实施例6 | 10g(实施例3) | 15g | 15g |
猪脑提取物 | γ-氨基丁酸 | 亚麻籽油粉 | |
对比例1 | 10g(实施例1) | 15g | -- |
对比例2 | 10g(实施例1) | -- | 15g |
时间/min | A/% | B/% | 流速/(mL/min) |
0 | 92 | 8 | 1.0 |
20 | 60 | 40 | 1.0 |
24 | 0 | 100 | 1.5 |
24.5 | 0 | 100 | 1.5 |
26.5 | 100 | 0 | 1.0 |
28 | 92 | 8 | 1.0 |
总氮标示含量% | γ-氨基丁酸标示含量% | |
实施例4 | 108.3 | 103.1 |
实施例5 | 110.2 | 102.9 |
实施例6 | 106.7 | 104.5 |
对比例1 | 105.3 | 104.6 |
对比例2 | 104.5 | / |
猪脑提取物(25g) | 162.5 | / |
分组 | 给药量 |
空白对照组(NC) | -- |
猪脑提取物 | 55mg/kg/d |
实施例6 | 55mg/kg/d |
对比例1 | 55mg/kg/d |
对比例2 | 55mg/kg/d |
组别 | 第1天错误次数 | 第2天潜伏期 | 第2天错误次数 |
NC | 4.58±2.39 | 46.79±29.53 | 3.47±1.28 |
猪脑提取物 | 4.35±2.27 | 89.63±76.05 | 2.72±1.59 |
实施例6 | 4.67±1.38 | 142.54±102.31 | 1.45±1.08 |
对比例1 | 4.59±2.08 | 134.72±87.03 | 2.64±1.78 |
对比例2 | 4.38±2.32 | 99.87±86.53 | 2.69±1.98 |
组合物来源 | 木糖醇含量/g | |
处方1 | 实施例4 | 20 |
处方2 | 实施例5 | 20 |
处方3 | 实施例6 | 50 |
处方4 | 对比例1 | 50 |
处方5 | 对比例2 | 50 |
处方6 | 对比例2 | 0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610547261.4A CN105998072B (zh) | 2016-07-08 | 2016-07-08 | 一种猪脑提取物、含有该猪脑提取物的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610547261.4A CN105998072B (zh) | 2016-07-08 | 2016-07-08 | 一种猪脑提取物、含有该猪脑提取物的组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105998072A true CN105998072A (zh) | 2016-10-12 |
CN105998072B CN105998072B (zh) | 2019-12-17 |
Family
ID=57109687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610547261.4A Active CN105998072B (zh) | 2016-07-08 | 2016-07-08 | 一种猪脑提取物、含有该猪脑提取物的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105998072B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109371081A (zh) * | 2018-03-06 | 2019-02-22 | 江西康宝医药生物科技有限公司 | 一种活性猪脑多肽的制备方法及其产品 |
CN109806279A (zh) * | 2017-11-17 | 2019-05-28 | 江西康宝医药生物科技有限公司 | 一种猪脑提取物融合中药改善记忆的口服液 |
CN111227234A (zh) * | 2020-03-03 | 2020-06-05 | 杭州华缔集团有限公司 | 一种具有辅助改善记忆功能的产品配方及其制备方法 |
CN111363771A (zh) * | 2020-03-18 | 2020-07-03 | 湖北瑞邦生物科技有限公司 | 一种具有强抗氧化能力猪脑提取物的生产工艺及猪脑提取物 |
WO2023136573A1 (ko) * | 2022-01-11 | 2023-07-20 | 유니메드제약주식회사 | 돼지뇌 효소가수분해물을 포함하는 기억력 개선, 인지능력 개선 또는 뇌신경질환 예방 또는 치료용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102166200A (zh) * | 2011-04-12 | 2011-08-31 | 罗诚 | 一种含猪脑蛋白水解物的冻干组合物及其制备方法 |
CN102526697A (zh) * | 2012-03-09 | 2012-07-04 | 张睿 | 一种吡拉西坦脑蛋白水解物滴丸及其制备方法 |
CN102552870A (zh) * | 2012-03-09 | 2012-07-11 | 张睿 | 一种脑蛋白水解物滴丸及其制备方法 |
CN103191403A (zh) * | 2013-04-02 | 2013-07-10 | 黑龙江迪龙制药有限公司 | 一种脑蛋白水解物的制备方法 |
CN105533726A (zh) * | 2015-12-09 | 2016-05-04 | 南京贝杉国际贸易有限公司 | 一种补充ω-3脂肪酸预防老年痴呆的配方食品及制备方法 |
-
2016
- 2016-07-08 CN CN201610547261.4A patent/CN105998072B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102166200A (zh) * | 2011-04-12 | 2011-08-31 | 罗诚 | 一种含猪脑蛋白水解物的冻干组合物及其制备方法 |
CN102526697A (zh) * | 2012-03-09 | 2012-07-04 | 张睿 | 一种吡拉西坦脑蛋白水解物滴丸及其制备方法 |
CN102552870A (zh) * | 2012-03-09 | 2012-07-11 | 张睿 | 一种脑蛋白水解物滴丸及其制备方法 |
CN103191403A (zh) * | 2013-04-02 | 2013-07-10 | 黑龙江迪龙制药有限公司 | 一种脑蛋白水解物的制备方法 |
CN105533726A (zh) * | 2015-12-09 | 2016-05-04 | 南京贝杉国际贸易有限公司 | 一种补充ω-3脂肪酸预防老年痴呆的配方食品及制备方法 |
Non-Patent Citations (1)
Title |
---|
DENG FENG,等: "Determination of peptide contents from cerebroprotein hydrolysates injection by amino acid analysis method", 《CHINESE JOURNAL OF PHARMACEUTICAL ANALYSIS》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109806279A (zh) * | 2017-11-17 | 2019-05-28 | 江西康宝医药生物科技有限公司 | 一种猪脑提取物融合中药改善记忆的口服液 |
CN109371081A (zh) * | 2018-03-06 | 2019-02-22 | 江西康宝医药生物科技有限公司 | 一种活性猪脑多肽的制备方法及其产品 |
CN111227234A (zh) * | 2020-03-03 | 2020-06-05 | 杭州华缔集团有限公司 | 一种具有辅助改善记忆功能的产品配方及其制备方法 |
CN111363771A (zh) * | 2020-03-18 | 2020-07-03 | 湖北瑞邦生物科技有限公司 | 一种具有强抗氧化能力猪脑提取物的生产工艺及猪脑提取物 |
CN111363771B (zh) * | 2020-03-18 | 2023-03-14 | 湖北瑞邦生物科技有限公司 | 一种具有强抗氧化能力猪脑提取物的生产工艺及猪脑提取物 |
WO2023136573A1 (ko) * | 2022-01-11 | 2023-07-20 | 유니메드제약주식회사 | 돼지뇌 효소가수분해물을 포함하는 기억력 개선, 인지능력 개선 또는 뇌신경질환 예방 또는 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
CN105998072B (zh) | 2019-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6828054B2 (ja) | ウォールナットオリゴペプチド粉、その調製方法と使用 | |
CN105998072A (zh) | 一种猪脑提取物、含有该猪脑提取物的组合物及其应用 | |
CN102802636B (zh) | 藏花素水解产物 | |
Koskovac et al. | Sea buckthorn oil—A valuable source for cosmeceuticals | |
JP6077305B2 (ja) | アミノ酸および植物を含む調製物およびアルコール解毒におけるその活性 | |
US20090068281A1 (en) | Composition, Functional Food and Pharmaceutical Composition for Improvement in Obesity | |
CN103725469B (zh) | 一种养生干红葡萄酒 | |
Shi et al. | The effects of supplementation with blueberry, cyanidin-3-O-β-glucoside, yoghurt and its peptides on obesity and related comorbidities in a diet-induced obese mouse model | |
Xu et al. | Effect of marine collagen peptides on physiological and neurobehavioral development of male rats with perinatal asphyxia | |
CN102994350B (zh) | 一种具有降血脂功能苦荞酒的制备方法 | |
CN113244282A (zh) | 包含人参果实提取物的脑激活组合物 | |
EP2893931A1 (en) | Growth hormone secretagogue | |
JP6735224B2 (ja) | アストロサイトのグルコース代謝活性化剤 | |
JP2006347952A (ja) | リパーゼ活性化作用を呈するアントラキノン誘導体、それからなる抗肥満薬、食品製剤及び化粧品 | |
CN106174494A (zh) | 一种组合物及其在制备健脑益智的产品中的应用 | |
CN109381473A (zh) | 黄芩苷在制备妊娠期糖尿病胎儿神经管畸形药物的应用 | |
BRPI0706865A2 (pt) | método para preparar extrato de shinyleaf yellowhorn e extrato de shinyleaf yellowhorn | |
CN114766565A (zh) | 一种缓解体力疲劳茶饮料及其制备方法 | |
CN107778332A (zh) | 唾液酸低聚糖及其制造方法、生发和骨骼肌形成促进剂 | |
JP5548379B2 (ja) | 花粉荷を含有する抗ヒスタミン剤 | |
JP6546048B2 (ja) | 解糖系活性化作用を呈するフェニルプロパノイド誘導体及びその製造方法 | |
CN101143203A (zh) | 一种具有护肝养胃功能的复方口服液 | |
JP2016531844A (ja) | モノアセチルジアシルグリセロール化合物を有効成分として含有する赤血球系細胞分化又は増殖促進用組成物 | |
US20240173371A1 (en) | Rhodiola crenulata compositions and methods of making the same | |
CN116640618B (zh) | 一种具有提升免疫力及健脑功效的牡丹肽、牡丹籽油肽及其制备方法、应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 313300 Building 2, No. 300 Xigang Road, Anji District, Huzhou inter provincial industrial transfer demonstration zone, Anji County, Huzhou City, Zhejiang Province Applicant after: Zhejiang Mingxi Biotechnology Co.,Ltd. Address before: Green Ting Road Yuhang District Cang Qian street of Hangzhou city Zhejiang province 311121 No. 1 Building 1 Room 302 Applicant before: HANGZHOU HUADI GROUP BIO-TECHNOLOGY CO.,LTD. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191126 Address after: 311200 No.156, guagang 1st Road, Guali Town, Xiaoshan District, Hangzhou City, Zhejiang Province Applicant after: HANGZHOU HUAJIN PHARMACEUTICAL Co.,Ltd. Address before: 313300 Building 2, No. 300 Xigang Road, Anji District, Huzhou inter provincial industrial transfer demonstration zone, Anji County, Huzhou City, Zhejiang Province Applicant before: Zhejiang Mingxi Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |